The nutritional supplement NR100157, designed to support the gastrointestinal tract, delayed CD4-cell decline in HIV-infected patients who had not yet initiated ART.
Given the rapid depletion of gut-associated CD4 cells following HIV infection, supplements that support gut integrity and immune function could have a beneficial effect on the health status of HIV-infected individuals. In a recent manufacturer-sponsored, randomized, controlled, double-blind trial, researchers assessed whether the nutritional supplement NR100157 provides systemic immunological benefits in such patients.
A total of 340 antiretroviral therapy (ART)-naive HIV-infected adults in Italy, the Netherlands, the U.K., Thailand, Brazil, Argentina, the U.S., and Australia were randomized to receive either the nutritional supplement or an isocaloric and isonitrogenous control product. At 52 weeks, the mean CD4-count decline from baseline …
Reviewing Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes